The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes of daratumumab, pomalidomide, and dexamethasone (DPd) followed by high-dose chemotherapy and autologous stem cell transplantation (HDCT/ASCT) in patients with relapsed/refractory myeloma RRMM.
 
Al-Ola A. Abdallah
Research Funding - Abbvie (Inst); Bristol-Myers Squibb/Medarex (Inst); Celgene (Inst); Sanofi (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - PSA vaccine patent
 
Ajoy Dias
No Relationships to Disclose
 
Hameem I Kawsar
No Relationships to Disclose
 
Ghulam Rehman Mohyuddin
No Relationships to Disclose
 
Monia Sigle
No Relationships to Disclose
 
Zahra Mahmoudjafari
Honoraria - Juno Therapeutics
Consulting or Advisory Role - Juno Therapeutics
 
Leyla Osman Shune
No Relationships to Disclose
 
Joseph McGuirk
Honoraria - Kite, a Gilead company; Novartis
Consulting or Advisory Role - Allovir; Juno Therapeutics; Kite, a Gilead company
Speakers' Bureau - Kite/Gilead
Research Funding - Astellas Pharma (Inst); Bellicum Pharmaceuticals (Inst); Fresenius Biotech (Inst); Gamida Cell (Inst); Kite, a Gilead company (Inst); Novartis (Inst); Novartis (Inst); Pluristem Therapeutics (Inst)
Travel, Accommodations, Expenses - Kite, a Gilead company
 
Siddhartha Ganguly
Honoraria - Kite, a Gilead company; Seagen
Speakers' Bureau - Kite, a Gilead company; Seagen
Research Funding - Daiichi Sankyo (Inst); Janssen (Inst)
Travel, Accommodations, Expenses - Kite, a Gilead company; Seagen